Basilea Pharmaceutica AG (BPMUF) Hisse Fiyat Tahmini

Basilea Pharmaceutica AG engages in the discovery, development, and commercialization of pharmaceutical products. The company is headquartered in Allschwil, Basel-Landschaft and currently employs 189 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. The company launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.